Tumorigenesis and tumor progression are associated with dysfunction of the nuclear transport machinery at the level of import and export receptors (karyopherins). Recent studies have shown that the nuclear import factor karyopherin-a2 (KPNA2) is a novel prognostic marker for poor prognosis in human breast cancer. Based on the well-defined hallmarks of cancer progression, we performed a detailed in vitro characterization of the phenotypic effects caused by KPNA2 overexpression and KPNA2 silencing in benign and malignant human breast cells. KPNA2 overexpression clearly increased proliferation of MCF7 tumor cells and further led to a reduction of cell-matrix adhesion in benign MCF10A cells, whereas cell migration was significantly increased (Po0.0001) in both tumor models. Remarkably, these individual effects of KPNA2 overexpression on proliferation, cell-matrix adhesion and migration resulted in an increased colony spreading of benign MCF10A breast cells and malignant MCF7 tumor cells (Po0.001), which is a hallmark of cancer progression. Conversely, RNA interference-mediated KPNA2 silencing caused a complete inhibition of MCF7 tumor cell proliferation and migration (Po0.0001). In addition, in these experiments apoptosis was increased (Po0.05) and formation of tumor cell colonies was reduced (Po0.01). Thus, KPNA2 overexpression provoked increased aggressiveness of malignant MCF7 breast tumor cells and induced a shift in benign MCF10A breast cells toward a malignant breast cancer phenotype. In conclusion, we demonstrate for the first time in experimental tumor models that forced KPNA2 expression drives malignant features relevant for breast cancer progression, while its silencing is required for the remission of those progressive phenotypes. This study gives clear evidence that KPNA2 acts as a novel oncogenic factor in human breast cancer, in vitro.
Tumorigenesis and tumor progression are associated with dysfunction of the nuclear transport machinery at the level of import and export receptors (karyopherins). Recent studies have shown that the nuclear import factor karyopherin-a2 (KPNA2) is a novel prognostic marker for poor prognosis in human breast cancer. Based on the well-defined hallmarks of cancer progression, we performed a detailed in vitro characterization of the phenotypic effects caused by KPNA2 overexpression and KPNA2 silencing in benign and malignant human breast cells. KPNA2 overexpression clearly increased proliferation of MCF7 tumor cells and further led to a reduction of cell-matrix adhesion in benign MCF10A cells, whereas cell migration was significantly increased (Po0.0001) in both tumor models. Remarkably, these individual effects of KPNA2 overexpression on proliferation, cell-matrix adhesion and migration resulted in an increased colony spreading of benign MCF10A breast cells and malignant MCF7 tumor cells (Po0.001), which is a hallmark of cancer progression. Conversely, RNA interference-mediated KPNA2 silencing caused a complete inhibition of MCF7 tumor cell proliferation and migration (Po0.0001). In addition, in these experiments apoptosis was increased (Po0.05) and formation of tumor cell colonies was reduced (Po0.01). Thus, KPNA2 overexpression provoked increased aggressiveness of malignant MCF7 breast tumor cells and induced a shift in benign MCF10A breast cells toward a malignant breast cancer phenotype. In conclusion, we demonstrate forIntroduction Eukaryotic nucleocytoplasmic transport is orchestrated by the interaction of karyopherins and cargo proteins. Transport cargos with a classical nuclear translocation sequence are potential substrates for the nuclear import receptor karyopherin-a2 (KPNA2). Together with importin-b, the KPNA2-bound cargo protein forms a ternary complex, which interacts with the nuclear pore complex and translocates into the nucleus (Gorlich, 1998; Lange et al., 2007) . The trimeric import complex dissociates after translocation due to binding of Ran-GTP to importin-b (Chook and Blobel, 2001) . Nuclear KPNA2 finally gets recycled into the cytoplasm by its export factor cellular apoptosis susceptibility (CAS) (Goldfarb et al., 2004) . Further, karyopherins have transport-independent key roles for the assembly of the nuclear pore complex, for mitosis and for S-phase progression, by regulation of microtubule polymerization (Mosammaparast and Pemberton, 2004) .
These findings indicate that nuclear protein transport is a complex process and that aberrant expression of nuclear transport factors like KPNA2s is capable of profound deregulation of gene transcription (Kau et al., 2004) . Indeed, altered, mutation-independent, subcellular localization of oncogenes or tumor suppressors has been observed in various cancer entities and emphasizes the importance of nuclear shuttling for proper cellular functions. For instance, the cytoplasmatic accumulation of the tumor suppressor p53 was detected in breast cancer (Lu et al., 2000) , colorectal cancer (Flamini et al., 1996) and ovarian cancer (Runnebaum et al., 1996) . In contrast, oncogenic nuclear factor kB (NFkB) accumulates in cancer cell nuclei in these tumor entities (Rayet and Gelinas, 1999) .
We previously discovered overexpression of KPNA2 mRNA in invasive breast cancer (Dahl et al., 2005) , and subsequently demonstrated that breast cancer patients with increased nuclear KPNA2 protein expression in tumor cells presented advanced tumor size, poor tumor differentiation, reduced overall and recurrence-free survival (Dahl et al., 2006) . Further gene expression studies revealed aberrant KPNA2 expression in premalignant and non-invasive ductal carcinomas in situ, indicating that this event occurs already in early stages of breast cancer development (Dankof et al., 2007; Klein et al., 2007) . The prognostic significance of KPNA2 overexpression was associated with node-positive, highrisk breast cancer patients, who exhibited aggressive tumors with poor differentiation, negative hormone receptor status, as well as Her2/Neu, EGFR and p53 overexpression (Gluz et al., 2008) . KPNA2 expression could therefore be useful as a novel biomarker for the identification of high-risk breast cancer patients and could be promising as a diagnostic tool for therapy optimization and improved risk assessment (Gluz et al., 2008) . In summary KPNA2 overexpression seems to correlate with basal-like and Her2/Neu tumor subtypes, which are generally characterized by poor prognosis and unfavorable therapy outcome (Perou et al., 2000; Sorlie et al., 2003) .
Interesting to note that KPNA2 expression has also been suggested as a biomarker for the diagnosis of nonsmall cell lung cancer (Wang et al., 2011) and being indicative of poor tumor differentiation and advanced tumor invasion in the esophageal squamous cell carcinomas (Sakai et al., 2010) . Furthermore, recent work identified KPNA2 as a potential prognostic marker for the progression of prostate cancer as well as therapy indicator for patients who underwent radical prostatectomy (Mortezavi et al., 2011) .
The so far defined biomarker qualities and biological functions of KPNA2 indicate that this nuclear transport protein may have an oncogenic potential that is capable of driving carcinogenesis, but there is still lack of information about the cellular consequences of KPNA2 overexpression for breast tumor cells. In order to shed light on the role of KPNA2 for tumorigenesis, we aimed to characterize the phenotypic outcome caused by KPNA2 overexpression and also KPNA2 expression loss, in human breast cell lines. We established gain-offunction and loss-of-function tumor models, based on benign MCF10A breast cells and malignant MCF7 breast cancer cells, to investigate cellular behavior with respect to adhesion, migration, colony spreading, proliferation and apoptosis.
Results

KPNA2 overexpression in gain-of-function in vitro models
First, the level of KPNA2 mRNA expression was determined in 10 human breast cancer cell lines to identify suitable recipients for transfection with a KPNA2 expression vector. Compared with non-transformed benign MCF10A and MCF12A cells, the majority of malignant breast cancer cell lines exhibited an increased KPNA2 expression level (median FC ¼ 3.9, standard deviation ( ± ) 4.3, range: 1.3-2.5) (Figure 1a ). Non-invasive MCF7 breast cancer cells had a typically increased KPNA2 mRNA (FC ¼ 5.9) and protein (FC ¼ 5.1) expression, compared with benign MCF10A cells (Figures 1a and b) . Because of their low and moderate average KPNA2 expression, MCF10A and MCF7 cells were chosen to generate KPNA2 gain-offunction models. In transiently transfected MCF10A/ KPNA2 cells, KPNA2 mRNA expression was raised up to 47.5-fold (data not shown), while KPNA2 protein expression was increased 17.4-fold compared with the MCF10A mock control in these cells ( Figure 1c) .
Next, MCF7 wild-type (WT) breast cancer cells were stably transfected with a tetracycline (TC)-regulated Tet-on KPNA2 expression vector system. The median FC of KPNA2 mRNA expression of all analyzed MCF7/KPNA2 clones (n ¼ 20) was 3.0 ± 1.1 (range: 1.3-5.7, Po0.001) after TC-induction, whereas eight tested MCF7/mock clones showed no differential KPNA2 expression (median FC ¼ 1.1 ± 0.2, range: 0.8-1.2) (Supplementary Figures 1a and b) . KPNA2 protein expression was also significantly increased after TCinduction (median FC ¼ 4.9 ± 0.7, range: 4.0-5.8, Po0.001) in a selection of five MCF7/KPNA2 clones, which were chosen for further analysis (Figure 1d ). Before the phenotypical analysis, the TC-induction procedure was optimized in MCF7/KPNA2 clones: a TC concentration of 1 mg/ml and an induction time of at least 24 h were followed by optimal gain of KPNA2 expression. TC-treatment did not influence KPNA2 expression neither in MCF7/mock clones nor in MCF7 WT cells, which demonstrated the lack of unspecific site effects (for detailed information, see Supplementary  Figures 1c and d) .
RNA interference-mediated KPNA2 knockdown in loss-of-function in vitro models In order to investigate the phenotypical impact of KPNA2, we further established a small-interfering RNA (siRNA)-mediated loss of KPNA2 expression in MCF7 tumor cells (MCF7DKPNA2). Commercial high quality and knockdown-validated siRNAs were used for all transfections. Using KPNA2-specific siRNAs a nearly complete loss of KPNA2 protein (À94%) was achieved after a 192 h treatment (Figure 1e ), whereas the knockdown of the respective mRNA (À93%) was already evident after 96 h (Supplementary Figure 2a) . For all following experiments, cells were treated with siRNAs for 192 h to assure an efficient KPNA2 protein knockdown. In contrast, the negative control exhibited KPNA2 expression similar to the MCF7 WT, which indicated the absence of unspecific side effects potentially caused by transfection procedures ( Supplementary Figure 2a) . Transfection efficiency was verified by fluorescence microscopically using a green fluorescent protein (GFP)-tagged, non-coding (nc)-siRNA ( Supplementary  Figures 2a and c) , which was also kept as control for unspecific side effects. A mitogen-activated protein kinase 1 (MAPK1)-siRNA was used additionally as positive control (Supplementary Figure 2b) . (Figure 2b ). That was evident also for TC-induced clone K9 and K12 (Figures 2c and e) . Moreover, KPNA2 induction of clone K11 resulted in an almost 10-fold increase of the nuclear KPNA2 protein fraction (median FC ¼ 9.9, Po0.05, Figure 2d ), which was quite higher than measured on the western blot level. In summary we found a significant increase of cytoplasmic and nuclear KPNA2 protein only in all TC-induced MCF7/KPNA2 clones selected for further experiments (median FC ¼ 2.7, Po0.001) (Figure 2f ). In contrast, no MCF7/mock clone (M) showed a significant change of cellular KPNA2 densities before and after TC-instance M7, samples, an ultra thin section of K9 demonstrates the typically observed proximity of IG-labeled KPNA2 protein to the nuclear membrane and nuclear pores (Figures 2g and h ). Thus, our TEM data clearly indicate that the overexpressed KPNA2 protein participates in nuclear shuttling of respective cargo substrate in all MCF7 clones.
KPNA2 overexpression forces cell adhesion of tumor cells
In the first set of functional experiments, we analyzed the capability of our tumor cell models to adhere on extracellular matrix-simulating surfaces. Malignant MCF7 WT cells showed a highly significant (Po0.001) decreased rate of cell-matrix adhesion of À35.6% ( KPNA2 overexpression forces tumor cell motility Next, the capability of tumor cells to repopulate a cell-free area was quantified using a 2-D scratch assay (Figures 4 and 5 ). MCF7 WT cells completely migrated into the defined scratch after 3 days, whereas MCF10A WT cells had repopulated only 21.1% of space (remaining cell-free area: 68.9%) (Figure 4a ). Malignant MCF7 tumor cells therefore presented the expectable, significantly higher cell migration capability (Po0.0001), compared with benign MCF10A breast cells.
KPNA2 overexpression in MC10A/KPNA2 cells resulted in an increased migratory activity of þ 43.9% (day 3, Po0.0001), directly compared with MCF10A/ mock clones ( Figure 4b ). We further found an increased migration of KPNA2 overexpressing MCF7/KPNA2 clones. Compared with their corresponding non-induced counterparts, TC-treated MCF7/KPNA2 clone 9 and 12 showed a highly significant increased migration capability of þ 26.3% (day 2, Po0.0001) and þ 33.9% (day 3, Po0.001), respectively (Figures 4c and d) . No significant alteration (P>0.05) was observed in the additional negative control (MCF7/mock clone M7) after the TC-treatment (Supplementary Figure 5a) . The overall comparison of all analyzed MCF7/KPNA2 clones (K6, K9, K11 and K12) emphasizes the significantly increased migration capability (P ¼ 0.0286), due to KPNA2 overexpression after day 1 ( þ 21%), day 2 ( þ 21.5%) and day 3 ( þ 25.1%) (Figure 4e After finding that KPNA2 overexpression forces migration, the influence of KPNA2 protein knockdown on MCF7 tumor cells was addressed. It turned out that the cell migration ability of our loss-of-function model KPNA2 promotes breast cancer progression in vitro E Noetzel et al was almost completely inhibited over a period of 4 days (Po0.0001, Figure 4f) . Interestingly, the number of viable MCF7DKPNA2 cells continuously decreased between day 0 and day 4 (Figure 5c ). In contrast, the negative control showed no decrease of cell number and repopulated the scratch after 3 days, which matched the MCF7 WT (see also Figure 4a ). A MAPK protein knockdown, also led to a high significantly reduced migration of MCF7 tumor cells, albeit in a less extent (Figure 4f ). compared with the negative control (MCF10A/mock) (Figure 6b ). Furthermore, all analyzed MCF7/KPNA2 clones (K6, K9, K11 and K12) showed increased colony numbers after KPNA2 induction as well, the increase being þ 36.3, þ 37, þ 32.6 and þ 42.9%, respectively (Figures 6c and d) . As expected, colony number of MCF7/mock clone 7 was not altered after the TCtreatment (À2.9%, Figures 6c and d) . A visual Figure 5 Imaging the migration process of MCF7 tumor cells, in vitro. Cell migration was daily documented for each sample until the complete scratch was repopulated with cells. Representative images demonstrating the migration progress between the starting point (day 0) and day 3 of MCF7/KPNA2 clone (a) K12 without (-) and (b) with ( þ ) TC-induction (for the complete migration process, see Supplementary Figure 5d ). (c, d) illustrate the migration progress of MCF7 tumor cells after KPNA2 protein knockdown ( þ KPNA2-siRNA) and after transfection with a nc-siRNA (negative control). Migration of the negative control on day 7 is not shown, because the cell-free area was already closed at day 4. White arrows: indication of increasing cell-free spots. Vertical lines indicating the initial outlines of scratches on day 0. Scale bar: 500 mm.
KPNA2 promotes breast cancer progression in vitro E Noetzel et al comparison of colony numbers of two MCF7/KPNA2 clones and MCF7/mock clone 7 is given in Figure 6c . The overall comparison more importantly demonstrated a highly significant median increment of colony spreading of MCF7/KPNA2 clones ( þ 40.6 ± 20.1%, range: from þ 15.84 to þ 86.7%, Po0.001) after KPNA2 induction, whereas the untreated counterparts just exhibited marginal changes (median: þ 0.47%±10.7%, range: À18.6 to þ 14.6%, P>0.05) (Figure 6e ). In contrast, RNA interference-mediated KPNA2 expression loss almost halved the ability of MCF7 cells to form tumor colonies (À44.8%, Po0.01), whereas the nc-siRNA negative control exhibited colonies similar to the MCF7 WT (D ¼ 2.3%, P>0.05) Figure 6f ).
KPNA2 overexpression stimulates proliferation of tumor cells
Additionally, the proliferation of our benign and malignant breast cancer models was analyzed. MCF7 WT tumor cells had a higher proliferation rate ( þ 15.8%) compared with benign MCF10A WT cells after 3 days, which is in concordance with its oncogenic phenotype (Figure 7a ). Cell proliferation was consider- KPNA2 promotes breast cancer progression in vitro E Noetzel et al ably increased after KPNA2 induction in MCF7/ KPNA2 clone K6 ( þ 37.8%) and K9 ( þ 12%), directly compared with the not-induced corresponding counterparts (Figures 7b and c) . Importantly, the additional negative control (MCF7/mock clone 7) exhibited no increase of proliferation after TC-treatment.
Loss of KPNA2 expression inhibits proliferation and forces apoptosis in tumor cells
After finding an association between KPNA2 overexpression and increased cell proliferation, the potential effect of a KPNA2 loss was addressed. RNA interference-mediated KPNA2 knockdown provoked a complete inhibition of proliferation in MCF7DKPNA2 cells, whereas proliferation of the negative control cells (nc-siRNA transfected) was similar to untransfected MCF7 WT cells (Figures 7d and e) . Compared with the starting point (day 0, absorption ¼ 0.2), absorption values of MCF7DKPNA2 cells, indicative of cell number, were lower at the endpoint measurement (day 3, absorption ¼ 0.1) and implicated a decreasing number of viable tumor cells (Figures 7d and e) .
Finally, we analyzed if apoptosis could probably contribute to the decreased cell number, therefore the activity of caspases 3 and 7 was measured (Figure 7f ). The caspases activation was significantly increased in MCF7DKPNA2 cells by 150%, compared with the corresponding nc-siRNA negative control (FC ¼ 1.0). This gain of apoptosis is also in concordance with the observed decrease of viable MCF7DKPNA2 cells during the migration process (see Figure 5c ).
KPNA2 overexpression is associated with the upregulation of putative downstream effectors relevant for malignant phenotypes
In order to explain the observed oncogenic effects of KPNA2 overexpression on MCF7 tumor cells in a more functional way, we analyzed the gene expression levels of several relevant downstream factors (Figure 8 ). In concordance with increased migration and proliferation rates the proliferating cell nuclear antigen (PCNA) mRNA (FC ¼ 4.7, Po0.01) and the Ras-related C3 botulinum toxin substrate 1 (RAC-1) mRNA (median FC ¼ 2.4, Po0.05) were significantly upregulated, respectively. Reduced apoptosis of TC-induced MCF7/ KPNA2 clones was accompanied by median 4.5-foldupregulated p65 mRNA (Po0.05). Gene expression of the oncogenic factor Octamer binding transcription factor 4 (OCT4) was also clearly increased (median FC ¼ 2.8, Po0.05) due to KPNA2 overexpression in all MCF7/KPNA2 clones, whereas benign MCF10A cells showed only weak expression (data not shown).
Discussion
Over the last decades the pioneering work of Gu¨nter Blobel and colleagues has deciphered the fundamental role of KPNA2 proteins in nuclear protein transport (Radu et al., 1995; Chook and Blobel, 2001 ). It has further been shown that malfunctions in nuclearcytoplasmic shuttling may contribute to carcinogenesis, for example, of breast and colon (Flamini et al., 1996; Lu et al., 2000) . Therefore, the objective of this study was to unveil the potential phenotypical consequences of KPNA2 overexpression in vitro, as frequently found in breast cancer patients ex vivo (Dahl et al., 2005) . As a prerequisite for such in depth functional characterization, gain-of-function models capable of overexpressing KPNA2 were required.
For this reason, we initially characterized KPNA2 expression in several human breast cancer cell lines. We revealed a first hint of a putative correlation between the KPNA2 expression amount and the malignancy of the analyzed tumor cell lines that is, that gradually increased expression seems almost to be associated with more aggressive cell characteristics. Based on these results, we generated in vitro tumor models with different KPNA2 expression levels mirroring in vivo stages of benign and malignant tumors. We thereby simulated firstly, both a low-and a high-aggressive tumor model by KPNA2 overexpression in MCF10A and MCF7 cells, and secondly a benign tumor cell model by KPNA2 silencing in MCF7 cells. Keeping in mind that the auto inhibitory domain of KPNA2 secures nuclear translocation only after interaction with a dedicated cargo protein and importin-b1 (Chook and Blobel, 2001; Harreman et al., 2003) , we importantly confirmed proper cytoplasmic/ nucleoplasmic shuttling of the transgenic KPNA2 protein. Thus, our in vitro MCF7/KPNA2 model was capable of overexpressing functional KPNA2 protein in physiological amounts, which provided a sound basis relevant for a tumor phenotypical analysis.
We focused on progressive characteristics especially relevant for the first steps of tumor development (Hanahan and Weinberg, 2000) . Overcoming cell adhesion is one of the crucial steps during the progression from benign lesions to invasive, metastatic tumor cells (Cavallaro and Christofori, 2001 ). Thus, we analyzed our cell models regarding their capability to adhere on an extracellular collagen-rich and matrix-simulating surface that is typical for tumor-associated microenvironments (Cavallaro and Christofori, 2001) . As expected, cell-matrix adhesion was significantly enhanced in nontransformed benign MCF10A WT cells, compared with malignant MCF7 WT breast tumor cells. In turn, KPNA2 overexpression in MCF10A/KPNA2 cells concurrently led to a significantly reduced cell-matrix adhesion. This shift suggests a functional association between increased KPNA2 expression and decreased cell adhesion-a feature which generally influences tumor cell motility (Hanahan and Weinberg, 2000) .
According to these findings, we addressed forced cell migration as another oncogenic property of tumor cells (Hanahan and Weinberg, 2000) . Cell migration was significantly increased in malignant MCF7 tumor cells, compared with the benign MCF10A breast cells. Forced KPNA2 overexpression led to a remarkable increase of cell migration both in the benign MCF10A/KPNA2 and malignant MCF7/KPNA2 clones, and involved enhanced RAC-1 and p65 gene expression-two factors being relevant for cell migration (Karin et al., 2002; Pankov et al., 2005) . After KPNA2 transfection, MCF10A featured a motile cell state reflecting a malignant phenotype, as migration was as abundant as in MCF7 WT breast tumor cells. Conversely, KPNA2 expression loss was associated with almost inhibited migration in malignant MCF7 tumor cells. The same effect has already been reported for lung cancer cells treated with KPNA2-siRNA (Wang et al., 2011) . Thus, the ability of breast tumor cells to migrate correlated positively with the degree of KPNA2 expression, which might be associated with the gradual nuclear shuttling of transcription factors relevant for cell migration signaling.
Both reduced cell-matrix adhesion and enhanced cellular motility are defined to be required for colony spreading, a benchmark for the invasiveness and metastasis of tumor cells (Hanahan and Weinberg, 2000) . We therefore determined the impact of KPNA2 expression on colony formation. As expected, malignant parental MCF7 tumor cells formed significantly more colonies, compared with benign MCF10A breast cells. In turn, KPNA2 overexpression led to a remarkable boost of benign MCF10A/KPNA2 breast cell colonies as well as to significant more MCF7/KPNA2 tumor cell colonies. Interestingly, induced KPNA2-silencing reduced the colony numbers and hence diminished spreading of breast tumor cells. These data suggest a functional linkage between the gradual increase of KPNA2 expression, activated RAC-1 and p65 transcription and rising colony formation in benign and malignant tumor cells.
Colony spreading is a complex process fueled by fundamental cellular processes. Besides adhesion and migration (Lauffenburger and Horwitz, 1996; Pawlak and Helfman, 2001) , it is also influenced by increased proliferative effects. For this reason, we additionally investigated this inherent feature of tumor cells (Hanahan and Weinberg, 2000) . Clearly increased cell proliferation rates were found in our MCF7/KPNA2 clones due to KPNA2 overexpression accompanied by increased PCNA expression-a proliferation marker (Hall et al., 1990 ) that has already been associated with poor survival outcome in breast cancer (Stuart-Harris et al., 2008) . Remarkably, KPNA2 silencing led to a complete inhibition of proliferation of MCF7DKPNA2 tumor cells. Note that the expression loss of MAPK1 a contributing factor for cell-cycle progression (Brunet et al., 1995) , decreased cell proliferation as expected, but did not cause full inhibition as found after a KPNA2 knockdown. In line with this, a KPNA2-silencingcaused reduction of cell proliferation was reported for prostate cancer cells as well (Mortezavi et al., 2011) . Additionally, KPNA2 gene silencing increased significantly the apoptosis rate of malignant MCF7DKPNA2 cells, which could also explain the decreased viability of MCF7DKPNA2 cells during the migration experiment. Our data clearly suggest a reciprocal association between KPNA2 expression and cell proliferation, and apoptosis, although further in depth analysis will be necessary to reveal the underlying pathways.
Pro-oncogenic effects of KPNA2 overexpression described here raise the question of the involved mechanisms behind. The nuclear import factor KPNA2 is in principle able to interact with any substrate containing a classical nuclear translocation sequence (Gorlich, 1998; Lange et al., 2007) , and might thereby be involved in nuclear shuttling of various transcription factors relevant for multiple cancer pathways. Such complexity of potential cellular networking complicates the designation of explicit target molecules. Nevertheless, we found a first hint that OCT4 could be part of KPNA2-mediated oncogenic cascades:
OCT4 is a key factor of embryonic stem cell fate by maintaining pluripotency (Ben Porath et al., 2008) . Further it is an important determinant for the malignant potential of tumor cells (Hu et al., 2008) and is accordingly not expressed in healthy and differentiated breast tissue (Ezeh et al., 2005) . We found only low OCT4 expression in benign MCF10A breast cells (data not shown), but clear expression in malignant MCF7 tumor cells, a finding that has been confirmed in a recent study (Hu et al., 2008) . More importantly, OCT4 expression was further increased due to KPNA2 overexpression in MCF7 tumor cells. OCT4 transcription could hence be influenced by gradual KPNA2 expression levels, and it is indicative that KPNA2-associated OCT4-downstream signaling may contribute to the malignant phenotype of human breast tumor cells.
So far, only little is known about proven KPNA2 interaction partners, but nuclear transport of the small RHO-GTPase RAC-1 has recently been shown to be mediated by KPNA2 (Sandrock et al., 2010) . Albeit RAC-1 is not a DNA-binding transcription factor, it has nuclear and cytoplasmic functions that regulate cellcycle progression (Olson et al., 1995) , adhesion and migration (Ridley et al., 2003; Raftopoulou and Hall, 2004; Pankov et al., 2005) . Thus, KPNA2 overexpression could be involved in malignant transformation, by RAC-1-binding or defining its nuclear concentration, which then aberrantly modulates relevant downstream effector cascades. The NFkB family member RelA (p65) promotes carcinogenesis due to antiapoptotic signaling, inducing proliferation and migration (Karin et al., 2002) and is shown to bind KPNA2 as well (Cunningham et al., 2003) . KPNA2 overexpression could therefore increase the nuclear translocation of p65, induce proliferation and migration, and hence be related to the aggressive phenotype of our in vitro tumor models. Conversely, KPNA2-silencing ablated proliferation and increased apoptosis, which could be associated with less KPNA2:p65 interaction as well. However, reciprocal effects between KPNA2 expression and p65-signaling should be addressed in future studies, but the upregulation of RAC-1 and p65 mRNA as a result of KPNA2 activity enhanced at least the presumption of KPNA2:RAC-1 or KPNA2:p65 interactions in these in vitro models.
In conclusion, our in vitro data complement the recently published prognostic impact of KPNA2 expression (Dahl et al., 2006; Dankof et al., 2007; Gluz et al., 2008) and support evidence that KPNA2 overexpression fosters the oncogenic properties of human breast cancer cells. Considering the biological function of KPNA2, possible molecular mechanisms behind these phenotypic alterations appear complex and remain to be deciphered. Irrespective of the underlying mechanisms, we demonstrate that the overexpression of solely one single factor, namely KPNA2, seems to be capable of provoking an increased aggressiveness of malignant MCF7 breast tumor cells and to induce a shift in benign MCF10A breast cells toward a malignant breast cancer phenotype. Future studies should focus on KPNA2-inducible xenograft models to characterize the oncogenic character of KPNA2, regarding invasiveness and metastasis in more depth. With respect to cancer therapy, the development of small molecular drugs targeting karyopherins, in particular KPNA2, is a promising approach in order to re-balance the subcellular localization of tumor-relevant proteins in tumor cells in vivo (Kau et al., 2004) . Therefore, a fine-tuned KPNA2 inhibitor could potentially represent a prospective powerful drug to limit the aggressiveness and growth of breast cancer cells.
Materials and methods
Cell line and reagents
Human breast cell lines MCF10A, MCF12A, ZR75-1, HS-578T, BT20, MDA-MB231, MDA-MB468, MCF7, SKBR3 and T47D were obtained from the American Type Culture Collection (ATCC, Rockville, MD, USA), cultured under recommended conditions and were regularly tested for mycoplasma infection using the PCR-based Venor GeM Mycoplasma Detection Kit (Minerva Biolabs, Berlin, Germany).
Nucleic acid extraction and reverse transcription PCR DNA and RNA were isolated from tissue samples or cell line pellets, and 1 mg of the total RNA was reverse-transcribed and processed as described recently (Noetzel et al., 2008) .
Semi-quantitative real-time PCR
Semi-quantitative PCR was performed using the iQ5-system together with the iQ SYBR GRN Supermix (Bio-Rad Laboratories, Munich, Germany). All reactions were performed in triplicates. For PCR conditions, primer sequences and evaluation details see Supplementary Table 1 .
Immunoblotting
Concentrations of protein lysates were assessed with a BCA Protein Assay (Thermo Scientific, Rockford, IL, USA). Total cell protein extraction was prepared by using lysis buffer (Invitrogen, Carlsbad, CA, USA). Cell fractioning was performed by using the ProteoJET Cytoplasmic & Nuclear Protein Extraction Kit (Thermo Scientific). The proteins were separated on a 4-12% polyacrylamide gel and transferred to poly(vinylidene difluoride) membranes (RT, 1 h, 0.2 mm, BioRad). The membranes were blocked in casein buffer (Roche Diagnostics, Mannheim, Germany) at 4 1C overnight. The membranes were then probed with the first antibody at RT for 1.5 h. Anti-KPNA2 (sc-6917, 1:500), anti-lamin-B (sc-6216, 1:500) antibodies were from Santa Cruz Biotechnology (Santa Cruz, CA, USA) and anti-GAPDH (MCA2427, 1:10 000) was obtained from ABD Serotech (Du¨sseldorf, Germany) and antib-actin (A5316, 1:5000) was obtained from Sigma-Aldrich (Deisenheim, Germany). Membranes were washed four times with phosphate-buffered saline containing 0.05% Tween 20 and incubated with horseradish peroxidase-conjugated secondary antibodies (Dako, Glostrup, Denmark), and the signal was detected by chemiluminescence (Pierce ECL, Thermo Scientific, Rockford, IL, USA). For detailed procedure information, see Supplementary Information 1.
RNA interference
Cells (1 Â 10 4 ) were transfected with HiPerfect transfection reagent (Roche) applying a combination of two sequence validated, and knockdown warranted KPNA2-siRNA (20 nM, each, 5 0 -ACGAATTGGCATGGTGGTGAA-3 0 and 5 0 -CCG GGTGTTGATTCCGAA-3 0 ) according to the manufacture's instructions (Qiagen, Hilden, Germany). After 96 h treatment cells were splitted and re-transfected with siRNA to guarantee efficient KPNA2 knockdown. Commercial MAKP1-siRNA (5 0 -AATGCTGACTCAAAGCTCTG-3 0 ) served as positive control (Qiagen). A green fluorescent protein-tagged, ncsiRNA (Qiagen) was kept as efficiency control and as control for unspecific side effects. After 48, 96, 120, 144, 168 and 192 h, samples were harvested for RNA and protein isolation.
Lowicryl embedding and IG labeling for transmission electron microscopy Cells were fixed in paraformaldehyde (0.2%. glutaraldehyde) and then underwent an automatic low-temperature Lowicryl embedding procedure. Ultra thin sections (90 nm) were transferred on nickel grates, first incubated with an anti-KPNA2 antibody and afterward incubated with an IG-labeled secondary antibody (1:25, Dako). For detailed procedure information see Supplementary Information 2.
Transfection of human breast cancer cells Stable, TC-inducible MCF7/KPNA2 clones were generated by subsequent transfection (FuGene HD transfection reagent, Roche) with the pcDNA6/TR expression vector and the pTREx-DEST30/KPNA2 expression vector (Invitrogen) that contains the full-length human KPNA2 complementary DNA (accession number: BC053343). MCF10A cells were transiently transfected (72 h) with the same KPNA2 expression vector alone. Transfectants were used either for functional analyses or single-cell cloned by limiting dilution under selection pressure (geneticine and blasticidine).
Cell adhesion assay
Cell-matrix adhesion experiments were performed as described previously (Paris et al., 2002) but slightly modified as follows: six-well plates were coated with 10 mg/ml Matrigel (BD Bioscience, Heidelberg, Germany). Cells (2.5 Â 10 5 cells/well) were plated in triplicate, incubated for 30 min (37 1C, 5% CO2) and gently washed three times with phosphate-buffered saline. Attached cells were fixed with 70% ethanol (10 min) and stained with 0.1% crystal violet solution (20 min). Cells were exhaustively washed with water and dried overnight. The dye was dissolved in 0.002% Triton X-100 in 100% isopropanol and carried over into a 96-well plate to measure the optical density at 590 nm.
Monolayer scratch assay Cells (6 Â 10 5 ) were plated into six-wells containing single culture inserts (2 Â 0.22 cm 2 , 70 ml, 500 mm cell-free gap, Ibidi, Martinsried, Germany). After 24 h the inserts were removed, generating a defined 500 mm scratch. Cells were washed twice gently (phosphate-buffered saline) and cultured with growth medium. Images of cell-free areas were taken with a CCD camera Colour View III (Olympus, Hamburg, Germany) fitted to a light microscope at 0, 24, 48, 72 and 96 h. Cell-free areas were quantified (mm 2 ) using the Axiovert software (Zeiss, Jena, Germany). All samples were performed in triplicates.
Colony formation assay Cells (1 Â 10 3 ) were seeded into six-well plates and maintained in growth medium. MCF10A/KPNA2 cells and MCF7/ KPNA2 clones were cultured under geneticine and blasticidine selection pressure, respectively. After 10 days colonies were fixed with 3.5% formaldehyde/80% methanol and stained with 0.1% crystal violet (20 min.). Colonies were photographed and counted using the ImageQuant software (GE Healthcare, Munich, Germany). All samples were performed in triplicates.
